Gkika Maria, Labiris Georgios, Kozobolis Vassilios
Eye Institute of Thrace and Department of Ophthalmology, Medical School of Democritus University of Thrace, Dragana, 68100, Alexandroupolis, Greece.
Int Ophthalmol. 2011 Aug;31(4):309-19. doi: 10.1007/s10792-011-9460-x. Epub 2011 Aug 17.
Corneal collagen cross-linking (CXL) using riboflavin and ultraviolet-A irradiation is a common method of tissue stabilization and has been developed primarily to address the need of treating keratoconus. CXL's promising results on keratoconus indicated that it might be effective in other corneal diseases as well. This new treatment promises a slowing effect on the progression of these diseases and its initial results show that it is safe and reasonably curative. The purpose of this review is to critically evaluate this treatment, to explore its benefits, to highlight its limitations in terms of efficacy and long-term safety and finally to identify areas for future research in this topic with a significant potential to change the way we treat our patients. In addition, in this unbiased review we try to bring together all the scientific information from both laboratory and clinical trials that have been conducted during recent years and to review the most recent publications regarding the therapeutic indications of CXL.
使用核黄素和紫外线A照射的角膜胶原交联（CXL）是一种常见的组织稳定方法，主要是为满足治疗圆锥角膜的需求而开发的。CXL在圆锥角膜上取得的有前景的结果表明，它在其他角膜疾病中可能也有效。这种新疗法有望减缓这些疾病的进展，其初步结果表明它是安全且有一定疗效的。本综述的目的是严格评估这种治疗方法，探讨其益处，突出其在疗效和长期安全性方面的局限性，最后确定该主题未来研究的领域，这些领域具有显著潜力，可能会改变我们治疗患者的方式。此外，在本公正的综述中，我们试图汇集近年来进行的实验室和临床试验的所有科学信息，并回顾有关CXL治疗适应症的最新出版物。
